Epithelial to Mesenchymal Transition is Associated with Rapamycin Resistance

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 May 7

PMID 25944619

Citations 15

Authors

Ashley M Holder

Argun Akcakanat

Farrell Adkins

Kurt Evans

Huiqin Chen

Caimiao Wei

Denai R Milton

Yisheng Li

Kim-Anh Do

Filip Janku

Funda Meric-Bernstam

Affiliations

Soon will be listed here.

Abstract

Rapamycin analogues have antitumor efficacy in several tumor types, however few patients demonstrate tumor regression. Thus, there is a pressing need for markers of intrinsic response/resistance and rational combination therapies. We hypothesized that epithelial-to-mesenchymal transition (EMT) confers rapamycin resistance. We found that the epithelial marker E-cadherin protein is higher in rapamycin sensitive (RS) cells and mesenchymal breast cancer cell lines selected by transcriptional EMT signatures are less sensitive to rapamycin. MCF7 cells, transfected with constitutively active mutant Snail, had increased rapamycin resistance (RR) compared to cells transfected with wild-type Snail. Conversely, we transfected two RR mesenchymal cell lines-ACHN and MDA-MB-231-with miR-200b/c or ZEB1 siRNA to promote mesenchymal-to-epithelial transition. This induced E-cadherin expression in both cell lines, and ACHN demonstrated a significant increase in RS. Treatment of ACHN and MDA-MB-231 with trametinib modulated EMT in ACHN cells in vitro. Treatment of MDA-MB-231 and ACHN xenografts with trametinib in combination with rapamycin resulted in significant growth inhibition in both but without an apparent effect on EMT. Future studies are needed to determine whether EMT status is predictive of sensitivity to rapalogs and to determine whether combination therapy with EMT modulating agents can enhance antitumor effects of PI3K/mTOR inhibitors.

Citing Articles

Molecular mechanisms of mTOR-mediated cisplatin response in tumor cells.

Maharati A, Rajabloo Y, Moghbeli M Heliyon. 2025; 11(1):e41483.

PMID: 39834411 PMC: 11743095. DOI: 10.1016/j.heliyon.2024.e41483.

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer.

Farmaki E, Nath A, Emond R, Karimi K, Grolmusz V, Cosgrove P Elife. 2023; 12.

PMID: 37772709 PMC: 10541180. DOI: 10.7554/eLife.85898.

Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy.

Cuellar-Vite L, Weber-Bonk K, Abdul-Karim F, Booth C, Keri R Cancers (Basel). 2022; 14(14).

PMID: 35884439 PMC: 9323520. DOI: 10.3390/cancers14143374.

CTCF Expression and Dynamic Motif Accessibility Modulates Epithelial-Mesenchymal Gene Expression.

Johnson K, Hussein S, Chakraborty P, Muruganantham A, Mikhail S, Gonzalez G Cancers (Basel). 2022; 14(1).

PMID: 35008373 PMC: 8750563. DOI: 10.3390/cancers14010209.

mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?.

Sun S Front Med. 2020; 15(2):221-231.

PMID: 33165737 DOI: 10.1007/s11684-020-0812-7.

References

Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills G . Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006; 5(10):2512-21. DOI: 10.1158/1535-7163.MCT-06-0334. View

Daemen A, Griffith O, Heiser L, Wang N, Enache O, Sanborn Z . Modeling precision treatment of breast cancer. Genome Biol. 2013; 14(10):R110. PMC: 3937590. DOI: 10.1186/gb-2013-14-10-r110. View

Virag P, Fischer-Fodor E, Perde-Schrepler M, Brie I, Tatomir C, Balacescu L . Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins. BMC Genomics. 2013; 14:480. PMC: 3776436. DOI: 10.1186/1471-2164-14-480. View

Elenbaas B, Spirio L, Koerner F, Fleming M, Zimonjic D, Donaher J . Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 2001; 15(1):50-65. PMC: 312602. DOI: 10.1101/gad.828901. View

Gonzalez-Angulo A, Hennessy B, Meric-Bernstam F, Sahin A, Liu W, Ju Z . Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics. 2011; 8(1):11. PMC: 3170272. DOI: 10.1186/1559-0275-8-11. View

Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A . Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007; 31(2):277-83. View

Haynes J, Srivastava J, Madson N, Wittmann T, Barber D . Dynamic actin remodeling during epithelial-mesenchymal transition depends on increased moesin expression. Mol Biol Cell. 2011; 22(24):4750-64. PMC: 3237619. DOI: 10.1091/mbc.E11-02-0119. View

Hirohashi S . Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998; 153(2):333-9. PMC: 1852964. DOI: 10.1016/S0002-9440(10)65575-7. View

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

10.

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

11.

Zhou B, Deng J, Xia W, Xu J, Li Y, Gunduz M . Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004; 6(10):931-40. DOI: 10.1038/ncb1173. View

12.

Hurteau G, Carlson J, Spivack S, Brock G . Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007; 67(17):7972-6. DOI: 10.1158/0008-5472.CAN-07-1058. View

13.

Wagle N, Grabiner B, Van Allen E, Hodis E, Jacobus S, Supko J . Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014; 4(5):546-53. PMC: 4122326. DOI: 10.1158/2159-8290.CD-13-0353. View

14.

Korpal M, Lee E, Hu G, Kang Y . The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008; 283(22):14910-4. PMC: 3258899. DOI: 10.1074/jbc.C800074200. View

15.

Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M . HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol. 2011; 226(9):2378-90. DOI: 10.1002/jcp.22574. View

16.

Saito A, Kanai Y, Maesawa C, Ochiai A, Torii A, Hirohashi S . Disruption of E-cadherin-mediated cell adhesion systems in gastric cancers in young patients. Jpn J Cancer Res. 1999; 90(9):993-9. PMC: 5926155. DOI: 10.1111/j.1349-7006.1999.tb00847.x. View

17.

Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C . Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012; 18(20):5796-805. DOI: 10.1158/1078-0432.CCR-12-1158. View

18.

Park S, Gaur A, Lengyel E, Peter M . The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008; 22(7):894-907. PMC: 2279201. DOI: 10.1101/gad.1640608. View

19.

Atefi M, Von Euw E, Attar N, Ng C, Chu C, Guo D . Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011; 6(12):e28973. PMC: 3237573. DOI: 10.1371/journal.pone.0028973. View

20.

Li Q, Chen C, Kapadia A, Zhou Q, Harper M, Schaack J . 3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen. J Biomol Screen. 2011; 16(2):141-54. DOI: 10.1177/1087057110392995. View